Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,688,656
  • Shares Outstanding, K 126,525
  • Annual Sales, $ 781,370 K
  • Annual Income, $ -197,880 K
  • EBIT $ 80 M
  • EBITDA $ 93 M
  • 60-Month Beta 0.37
  • Price/Sales 3.35
  • Price/Cash Flow N/A
  • Price/Book 6.52

Options Overview Details

View History
  • Implied Volatility 57.24% (-3.97%)
  • Historical Volatility 113.52%
  • IV Percentile 24%
  • IV Rank 21.92%
  • IV High 97.27% on 07/28/25
  • IV Low 46.00% on 09/04/25
  • Expected Move (DTE 15) 2.50 (11.26%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 310
  • Volume Avg (30-Day) 428
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 58,725
  • Open Int (30-Day) 61,149
  • Expected Range 19.69 to 24.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.39
  • Number of Estimates 11
  • High Estimate -0.23
  • Low Estimate -0.55
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.75 +18.32%
on 11/07/25
22.45 -1.16%
on 12/04/25
+1.72 (+8.40%)
since 11/04/25
3-Month
18.75 +18.32%
on 11/07/25
30.48 -27.20%
on 10/28/25
-6.46 (-22.55%)
since 09/04/25
52-Week
16.10 +37.83%
on 05/15/25
35.72 -37.88%
on 12/09/24
-11.94 (-34.98%)
since 12/04/24

Most Recent Stories

More News
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent...

APLS : 22.19 (+4.42%)
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:...

APLS : 22.19 (+4.42%)
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous...

APLS : 22.19 (+4.42%)
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November...

APLS : 22.19 (+4.42%)
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI ® (pegcetacoplan) in the first two months since...

APLS : 22.19 (+4.42%)
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission ( UPCR ≤0.5 g/g) achieved in one-third...

APLS : 22.19 (+4.42%)
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced...

APLS : 22.19 (+4.42%)
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Impedimed Limited (OtherIPDQF) and Humana (HUM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report), Impedimed Limited (IPDQF – Research Report) and Humana (HUM – Research...

HUM : 253.02 (-1.52%)
APLS : 22.19 (+4.42%)
IPDQF : 0.0118 (-63.69%)
RBC Capital Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

In a report released on October 8, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals. The company’s shares closed yesterday at $25.73.Elevate Your Investing Strategy: Take...

APLS : 22.19 (+4.42%)
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

In a report released today, Biren Amin from Piper Sandler maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Friday at $23.80.Elevate...

APLS : 22.19 (+4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 24.00
2nd Resistance Point 23.22
1st Resistance Point 22.71
Last Price 22.19
1st Support Level 21.42
2nd Support Level 20.64
3rd Support Level 20.13

See More

52-Week High 35.72
Fibonacci 61.8% 28.23
Fibonacci 50% 25.91
Fibonacci 38.2% 23.59
Last Price 22.19
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar